相似文献
1
Targeting Signaling Pathways in Inflammatory Breast Cancer.
Cancers (Basel). 2020 Sep 1;12(9):2479. doi: 10.3390/cancers12092479.
2
Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
Clin Breast Cancer. 2016 Apr;16(2):113-22.e1. doi: 10.1016/j.clbc.2015.11.006. Epub 2015 Dec 1.
3
Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer.
Breast Cancer Res. 2019 May 6;21(1):59. doi: 10.1186/s13058-019-1140-1.
4
Toward precision medicine in inflammatory breast cancer.
Transl Cancer Res. 2019 Oct;8(Suppl 5):S469-S478. doi: 10.21037/tcr.2019.05.04.
5
The tumor microenvironment and inflammatory breast cancer.
J Cancer. 2017 Jul 3;8(10):1884-1891. doi: 10.7150/jca.17595. eCollection 2017.
6
Inflammatory breast cancer biology: the tumour microenvironment is key.
Nat Rev Cancer. 2018 Aug;18(8):485-499. doi: 10.1038/s41568-018-0010-y.
7
Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
Breast Cancer Res. 2018 Aug 7;20(1):88. doi: 10.1186/s13058-018-1007-x.
8
Biomarkers for Inflammatory Breast Cancer: Diagnostic and Therapeutic Utility.
Breast Cancer (Dove Med Press). 2020 Oct 14;12:153-163. doi: 10.2147/BCTT.S231502. eCollection 2020.
9
Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
Mol Cancer. 2017 Mar 7;16(1):57. doi: 10.1186/s12943-017-0621-z.
10
Pathological and molecular characteristics of inflammatory breast cancer.
Transl Cancer Res. 2019 Oct;8(Suppl 5):S449-S456. doi: 10.21037/tcr.2019.03.24.
引用本文的文献
1
Synthesis and Biological Evaluation of Herceptin-Conjugated Liposomes Loaded with Lipocalin-2 siRNA for the Treatment of Inflammatory Breast Cancer.
Pharmaceuticals (Basel). 2025 Jul 17;18(7):1053. doi: 10.3390/ph18071053.
2
AXL promotes inflammatory breast cancer progression by regulating immunosuppressive macrophage polarization.
Breast Cancer Res. 2025 May 6;27(1):70. doi: 10.1186/s13058-025-02015-8.
3
Steady-State Delivery and Chemical Modification of Food Nutrients to Improve Cancer Intervention Ability.
Foods. 2024 Apr 28;13(9):1363. doi: 10.3390/foods13091363.
4
Synthesis of novel nonsteroidal anti-inflammatory galloyl β-sitosterol-loaded lignin-capped Ag-based drug.
Inflammopharmacology. 2024 Apr;32(2):1333-1351. doi: 10.1007/s10787-023-01390-y. Epub 2023 Nov 23.
5
Applying a Gene Reversal Rate Computational Methodology to Identify Drugs for a Rare Cancer: Inflammatory Breast Cancer.
Cancer Inform. 2023 Oct 14;22:11769351231202588. doi: 10.1177/11769351231202588. eCollection 2023.
6
Improved Rate of Negative Margins for Inflammatory Breast Cancer Using Intraoperative Frozen Section Analysis.
Cancers (Basel). 2023 Sep 16;15(18):4597. doi: 10.3390/cancers15184597.
7
Comprehensive Characterization of Immune Cell Infiltration Characteristics and Drug Sensitivity Analysis in Inflammatory Breast Cancer Based on Bioinformatic Strategy.
Biochem Genet. 2024 Apr;62(2):1021-1039. doi: 10.1007/s10528-023-10460-3. Epub 2023 Jul 30.
8
Stabilization of E-cadherin adhesions by COX-2/GSK3β signaling is a targetable pathway in metastatic breast cancer.
JCI Insight. 2023 Mar 22;8(6):e156057. doi: 10.1172/jci.insight.156057.
9
Transformer for Gene Expression Modeling (T-GEM): An Interpretable Deep Learning Model for Gene Expression-Based Phenotype Predictions.
Cancers (Basel). 2022 Sep 29;14(19):4763. doi: 10.3390/cancers14194763.
10
Inflammatory Breast Cancer: The Secretome of HCMV Tumor-Associated Macrophages Enhances Proliferation, Invasion, Colony Formation, and Expression of Cancer Stem Cell Markers.
Front Oncol. 2022 Jun 30;12:899622. doi: 10.3389/fonc.2022.899622. eCollection 2022.
本文引用的文献
1
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.
Oncologist. 2020 Jun;25(6):e909-e919. doi: 10.1634/theoncologist.2018-0611. Epub 2020 Jan 31.
2
Nomogram for predicting the overall survival of patients with inflammatory breast cancer: A SEER-based study.
Breast. 2019 Oct;47:56-61. doi: 10.1016/j.breast.2019.05.015. Epub 2019 Jul 17.
3
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.
Br J Cancer. 2019 Jun;120(12):1105-1112. doi: 10.1038/s41416-019-0473-y. Epub 2019 May 17.
4
Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer.
Cancer Immunol Res. 2019 Jun;7(6):1025-1035. doi: 10.1158/2326-6066.CIR-18-0619. Epub 2019 May 1.
5
The level of synovial AXL expression determines the outcome of inflammatory arthritis, possibly depending on the upstream role of TGF-β1.
Rheumatology (Oxford). 2019 Mar 1;58(3):536-546. doi: 10.1093/rheumatology/key337.
6
NMT1 inhibition modulates breast cancer progression through stress-triggered JNK pathway.
Cell Death Dis. 2018 Nov 16;9(12):1143. doi: 10.1038/s41419-018-1201-x.
7
Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer.
JAMA Oncol. 2018 Sep 1;4(9):1207-1213. doi: 10.1001/jamaoncol.2018.1436.
8
International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.
J Cancer. 2018 Apr 6;9(8):1437-1447. doi: 10.7150/jca.23969. eCollection 2018.
9
Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer.
Ann Surg Oncol. 2018 Jul;25(7):1783-1785. doi: 10.1245/s10434-018-6486-6. Epub 2018 Apr 18.
10
Blocking Interleukin (IL)4- and IL13-Mediated Phosphorylation of STAT6 (Tyr641) Decreases M2 Polarization of Macrophages and Protects Against Macrophage-Mediated Radioresistance of Inflammatory Breast Cancer.
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):1034-1043. doi: 10.1016/j.ijrobp.2017.11.043. Epub 2017 Dec 7.
Zotero 插件